These treatments should be offered to adults who meet all of the following: At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease) BMI of 35 kg/m or above (or 32.5 kg/m or above for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean backgrounds) Access to a specialist weight management service that provides multidisciplinary support, including dietary advice, physical activity programmes, and behavioural interventions Treatment is typically time-limited to up to 2 years Previous unsuccessful attempts at weight loss through lifestyle measures alone Orlistat may be considered for adults with a BMI of 28 kg/m or above with associated risk factors (such as type 2 diabetes or cardiovascular disease), or 30 kg/m or above without additional risk factors
[1] But lately, theres a growing buzz around Rybelsus, the once-daily pill form of semaglutide
It is not just safe
A study looking at what happens when you stop weight loss treatment found that people often return to their starting weight in 1.7 years after stopping semaglutide and tirzepatide (the active ingredient in Mounjaro)
Studies assessing ulcer healing, tissue regrowth, or restoration of normal gut architecture often need at least 2-4 weeks to show major effects
